REDWOOD CITY, Calif.--(BUSINESS WIRE)--HeartFlow, Inc., a medical technology company uniquely positioned at the intersection of advanced artificial intelligence (AI) capabilities and healthcare, today announced it has been named to Fast Company’s prestigious annual list of the World’s Most Innovative Companies for 2019. The list honors the businesses making the most profound impact on both industry and culture.
HeartFlow is recognized in the Artificial Intelligence category for the HeartFlow Analysis, a non-invasive, cardiac test that leverages deep learning, a form of AI, combined with the efforts of highly trained human analysts to create a personalized 3D model of the heart. It applies advanced algorithms to solve millions of complex equations to assess the impact of blockages on blood flow to the heart, helping physicians visualize the problem and determine the best treatment pathway for each patient. With the HeartFlow Analysis, HeartFlow is driving towards a new standard of care for the diagnosis and treatment of heart disease – the number one killer worldwide according to the Centers for Disease Control.
The HeartFlow technology has been demonstrated to significantly reduce unnecessary and invasive diagnostic coronary angiography procedures, which can be associated with bleeding, stroke, major blood vessel damage and other serious complications. By non-invasively identifying which patients do and do not need intervention, clinicians can reduce unnecessary invasive testing, reduce healthcare system costs and improve patient quality of life.1 To date, clinicians have used the HeartFlow Analysis for more than 30,000 patients to aid in the diagnosis of heart disease.
“At HeartFlow, we’re taking the best of cutting-edge technology and applying it to help physicians save lives,” said John H. Stevens, M.D., president and chief executive officer of HeartFlow. “We’ve only just scratched the surface of the tremendous potential of AI in healthcare and we’re eager to bring our innovative approach to diagnosing and treating heart disease to the world.”
About HeartFlow, Inc.
HeartFlow, Inc. is a medical technology company redefining the way heart disease is diagnosed and treated. Our non-invasive HeartFlow FFRct Analysis leverages deep learning to create a personalized 3D model of the heart. By using this model, clinicians can better evaluate the impact a blockage has on blood flow and determine the best treatment for patients. Our technology is reflective of our Silicon Valley roots and incorporates decades of scientific evidence with the latest advances in artificial intelligence. The HeartFlow FFRct Analysis is commercially available in the United States, Canada, Europe and Japan. For more information, visit www.heartflow.com.
About Fast Company
Fast Company is the only media brand fully dedicated to the vital intersection of business, innovation, and design, engaging the most influential leaders, companies and thinkers on the future of business. Since 2011, Fast Company has received some of the most prestigious editorial and design accolades, including the American Society of Magazine Editors (ASME) National Magazine Award for “Magazine Of The Year,” Adweek’s Hot List for “Hottest Business Publication,” and six gold medals and 10 silver medals from the Society of Publication Designers. The editor-in-chief is Stephanie Mehta and the publisher is Amanda Smith. Headquartered in New York City, Fast Company is published by Mansueto Ventures LLC, along with our sister publication Inc., and can be found online at www.fastcompany.com.
1 Douglas PS, DeBruyne B, Pontone G., Patel MR, et al. One-year outcomes of FFRCT-guided care in patients with suspected coronary disease: The PLATFORM Study. J Am Coll Cardiol. 2016;68(5),435-45.
